Table of Contents
Leukemia Research and Treatment
Volume 2017, Article ID 3460892, 6 pages
https://doi.org/10.1155/2017/3460892
Research Article

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation

1Department of Pharmacy, West Virginia University Hospitals, Morgantown, WV, USA
2Osborn Hematopoietic Malignancy and Transplantation Program, MBRCC, West Virginia University, Morgantown, WV, USA
3Department of Biostatistics, West Virginia University, Morgantown, WV, USA

Correspondence should be addressed to Aaron Cumpston; gro.enicidemuvw@anotspmuc

Received 14 March 2017; Accepted 17 May 2017; Published 11 June 2017

Academic Editor: Daniela Cilloni

Copyright © 2017 Morgan Belling et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Morgan Belling, Abraham S. Kanate, Alexandra Shillingburg, et al., “Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation,” Leukemia Research and Treatment, vol. 2017, Article ID 3460892, 6 pages, 2017. https://doi.org/10.1155/2017/3460892.